Terms: = Lung cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
3234 results:
1. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
2. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract] [Full Text] [Related]
3. Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach.
Alsaiari AA; Gharib AF; Bakhuraysah MM; Alrehaili AA; Algethami SM; Alsaif HA; Al Harthi N; Hakami MA
Med Oncol; 2024 Apr; 41(5):117. PubMed ID: 38630325
[TBL] [Abstract] [Full Text] [Related]
4. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
5. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
6. Promoting the Anticancer Activity with Multidentate Furan-2-Carboxamide Functionalized Aroyl Thiourea Chelation in Binuclear Half-Sandwich Ruthenium(II) Complexes.
Thangavel SK; Mohamed Kasim MS; Rengan R
Inorg Chem; 2024 Apr; 63(16):7520-7539. PubMed ID: 38590210
[TBL] [Abstract] [Full Text] [Related]
7. Establishment of a Novel cancer-Specific Anti-her2 Monoclonal Antibody H
Kaneko MK; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
[TBL] [Abstract] [Full Text] [Related]
8. Universal CAR T cells targeted to her2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Nagy L; Mezősi-Csaplár M; Rebenku I; Vereb G; Szöőr Á
Front Immunol; 2024; 15():1365172. PubMed ID: 38562932
[TBL] [Abstract] [Full Text] [Related]
9. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes of the patients with metastatic male breast cancer.
Dogan I; Khanmammadov N; Ozkurt S; Aydiner A; Saip P
J Cancer Res Ther; 2024 Jan; 20(1):98-102. PubMed ID: 38554305
[TBL] [Abstract] [Full Text] [Related]
11. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-lung01): primary results of the her2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
[TBL] [Abstract] [Full Text] [Related]
12. Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI).
Cortés-Ibáñez FO; Johnson T; Mascalchi M; Katzke V; Delorme S; Kaaks R
Sci Rep; 2024 Mar; 14(1):7197. PubMed ID: 38531926
[TBL] [Abstract] [Full Text] [Related]
13. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
14. Discovery of Novel 5,6-Dihydro-4
Yang L; Li Y; Du Y; Guo Y; Guo Z; Liu B; Liu J; Liu Y; Niu H; Sun Y; Yan H; Yang Y; Yu S; Zhang Y; Zhang Y; Zheng K; Zheng N; Zhang X; Zhang Q; Hu L
J Med Chem; 2024 Apr; 67(7):5662-5682. PubMed ID: 38518121
[TBL] [Abstract] [Full Text] [Related]
15. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
16. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
[TBL] [Abstract] [Full Text] [Related]
17. [A Case of Breast cancer That Developed Pulmonary Tumor Thrombotic Microangiopathy during Adjuvant Chemotherapy].
Okano K; Suzuki T; Abe A; Itaya A; Kameyama Y; Matsumoto S; Hakamada K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):283-285. PubMed ID: 38494809
[TBL] [Abstract] [Full Text] [Related]
18. [Advances in the treatment of anti-her-2 antibody drug conjugates in pan-tumor with low her-2 expression].
Wei T; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
[TBL] [Abstract] [Full Text] [Related]
19. The Role of
Chu J; Tang S; Li T; Fan H
Front Biosci (Landmark Ed); 2024 Feb; 29(2):73. PubMed ID: 38420798
[TBL] [Abstract] [Full Text] [Related]
20. EGFR and erbb2 Exon 20 Insertion Mutations in Chinese Non-small Cell lung cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
[TBL] [Abstract] [Full Text] [Related]
[Next]